SELLAS Life Sciences Group Inc
SLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.33B
Close$
$0.65
94.3% downside
Current Fair Value
94.3% downsideOvervalued by 94.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.33 Billion |
|---|---|
| Enterprise Value | $2.19 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.25 |
| Beta | 2.57 |
| Outstanding Shares | 189,183,620 |
Return
| Return on Equity | -23.58% |
|---|---|
| Return on Assets | -22.33% |
| Return on Invested Capital | -24.60% |
Valuation & Multiples
| P/E Ratio | -54.61 |
|---|---|
| PEG | -120.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -64.68 |
| Enterprise Value to Net Income | -68 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 108.59% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.21%▼ 38.06% |
|---|---|
| Total Invested | $28.24M▼ 97.40% |
| Investors Holding | 35▼ 199.00% |
ESG Score
No data
About SELLAS Life Sciences Group Inc
7 employeesSELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Ketteri...